A REVIEW ON NOVEL MEDICATION ADVANCEMENT IN THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), DIABETICS, DILATED CARDIOMYOPATHY

Drug development is the process of bringing a new drug to market after a lead chemical has been identified through drug discovery. Before a medicine is available for clinical use, the drug development process can take up to 20 years and cost as much as $3 billion USD.As we see that recent drug developments in Systemic Lupus Erythematosus (SLE). IVRADINE is a unique agent that is distinct from beta-blockers as it reduces heart rate without affecting myocardial contractility or vascular tone. The main efficacy endpoint was major adverse cardiac events (MACE) at 30 days and 6 months, defined as a composite of cardiac death, myocardial infarction, and HF hospitalizations.

Keywords: ANIFROLUMAB, TIRZETATIDE, IVABRADINE, VYMADA.